After more than three decades of joint adventure for Japan's Kirin Holdings Co. Ltd. (KHK) and Thousand Oaks, Calif.-based Amgen Inc., the partners are winding down a JV with a $780 million payout to redeem the Asian conglomerate's shares in the business, Kirin-Amgen Inc. The business will now become a wholly owned subsidiary of Amgen. KHK said that it will continue to develop, manufacture and sell pharmaceuticals licensed by Kirin-Amgen.